Search

Thomas M Stormann

age ~66

from Salt Lake City, UT

Get Report
Also known as:
  • Thomas M Storman
  • Tom Stormann
Phone and address:
1327 Harrison Ave, Salt Lake City, UT 84105
801 583-8005
Related to:
Connected to:

Thomas Stormann Phones & Addresses

  • 1327 Harrison Ave, Salt Lake City, UT 84105 • 801 583-8005 • 801 583-8596
  • Salt Lake Cty, UT
  • Bethesda, MD
  • Baltimore, MD
  • Lawrence, KS
  • San Diego, CA

Us Patents

  • Metabotropic Glutamate Receptor Antagonists And Their Use For Treating Central Nervous System Diseases

    view source
  • US Patent:
    6429207, Aug 6, 2002
  • Filed:
    May 19, 2000
  • Appl. No.:
    09/573347
  • Inventors:
    Bradford C. Van Wagenen - Salt Lake City UT
    Scott T. Moe - Salt Lake City UT
    Daryl L. Smith - Salt Lake City UT
    Susan M. Sheehan - Dexter MI
    Irina Shcherbakova - Salt Lake City UT
    Richard Travato - Salt Lake City UT
    Ruth Walton - Ogden UT
    Robert Barmore - Salt Lake City UT
    Eric G. Delmar - Salt Lake City UT
    Thomas M. Stormann - Salt Lake City UT
  • Assignee:
    NPS Pharmaceuticals, Inc. - Salt Lake City UT
  • International Classification:
    A61K 31498
  • US Classification:
    514249, 544355, 544354, 544353
  • Abstract:
    The present invention provides compounds, and pharmaceutical compositions containing those compounds, that are active at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

  • Human Metabotropic Glutamate Receptor

    view source
  • US Patent:
    6534287, Mar 18, 2003
  • Filed:
    Oct 24, 2000
  • Appl. No.:
    09/695481
  • Inventors:
    Karen J. Krapcho - Salt Lake City UT
    Thomas M. Stormann - Salt Lake City UT
    Cynthia Levinthal - Salt Lake City UT
    Lance G. Hammerland - Salt Lake City UT
  • Assignee:
    NPS Pharmaceuticals, Inc. - Salt Lake City UT
  • International Classification:
    C12P 2106
  • US Classification:
    435 691, 435 6, 4352523, 4353201, 435325, 536 235, 530350
  • Abstract:
    A novel human metabotropic glutamate receptor (mGluR) protein is identified, sequenced, and cloned. The receptor may be used to screen for compounds that modulate the activity of the mGluR. The recombinant mGluR as well as compounds that modulate mGluR activity may be used in the diagnosis and treatment of neurological disorders and diseases.

  • Nucleic Acids Encoding Mglur/Car Chimera

    view source
  • US Patent:
    6534289, Mar 18, 2003
  • Filed:
    Nov 8, 1999
  • Appl. No.:
    09/435897
  • Inventors:
    Forrest H. Fuller - La Jolla CA
    Karen J. Krapcho - Salt Lake City UT
    Lance G. Hammerland - Bountiful UT
    Laura L. Storjohann - Salt Lake City UT
    Thomas M. Stormann - Salt Lake City UT
  • Assignee:
    NPS Pharmaceuticals, Inc. - Salt Lake City UT
  • International Classification:
    C12P 2104
  • US Classification:
    435 697, 435 691, 435366, 4353201, 435325, 536 235, 536 231, 530350
  • Abstract:
    The present invention provides chimeric receptors. The chimeric receptors comprise at least one region homologous to a region of a metabotropic glutamate receptor and at least one region homologous to a region of a calcium receptor. The invention also includes methods of preparing such chimeric receptors, and methods of using such receptors to identify and characterize compounds which modulate the activity of metabotropic glutamate receptors or calcium receptors. The invention also relates to compounds and methods for modulating metabotropic glutamate receptor activity and binding to metabotropic glutamate receptors. Modulation of metabotropic glutamate receptor activity can be used for different purposes such as treating neurological disorders and diseases, inducing an analgesic effect, cognition enhancement, and inducing a muscle-relaxant effect.

  • Heteropolycyclic Compounds And Their Use As Metabotropic Glutamate Receptor Antagonists

    view source
  • US Patent:
    6660753, Dec 9, 2003
  • Filed:
    Feb 19, 2002
  • Appl. No.:
    10/076618
  • Inventors:
    Bradford Van Wagenen - Salt Lake City UT
    Thomas M. Stormann - Salt Lake City UT
    Scott T. Moe - Salt Lake City UT
    Susan M. Sheehan - Salt Lake City UT
    Donald A. McLeod - Salt Lake City UT
    Daryl L. Smith - Salt Lake City UT
    Methvin Benjamin Isaac - Ontario, CA
    Abdelmalik Slassi - Ontario, CA
  • Assignee:
    NPS Pharmaceuticals, Inc. - Salt Lake City UT
  • International Classification:
    C07D40102
  • US Classification:
    514340, 5462691
  • Abstract:
    The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

  • Metabotropic Glutamate Receptor Antagonists And Their Use For Treating Central Nervous System Diseases

    view source
  • US Patent:
    7053104, May 30, 2006
  • Filed:
    Aug 5, 2002
  • Appl. No.:
    10/211523
  • Inventors:
    Bradford C. Van Wagenen - Salt Lake City UT, US
    Scott T. Moe - Ann Arbor MI, US
    Daryl L. Smith - Fishers IN, US
    Susan M. Sheehan - Dexter MI, US
    Irina Shcherbakova - Salt Lake City UT, US
    Ruth Walton - Bountiful UT, US
    Richard Trovato - Salt Lake City UT, US
    Robert Barmore - Salt Lake City UT, US
    Eric G. Delmar - Salt Lake City UT, US
    Thomas M. Stormann - Salt Lake City UT, US
  • Assignee:
    NPS Pharmaceuticals, Inc. - Salt Lake City UT
  • International Classification:
    A61K 31/47
    C07D 215/14
  • US Classification:
    514311, 546169, 546 90, 514291
  • Abstract:
    The present invention provides compounds, and pharmaceutical compositions containing those compounds, that are active at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

  • Heteropolycyclic Compounds And Their Use As Metabotropic Glutamate Receptor Antagonists

    view source
  • US Patent:
    7112595, Sep 26, 2006
  • Filed:
    Nov 3, 2003
  • Appl. No.:
    10/699563
  • Inventors:
    Bradford Van Wagenen - Salt Lake City UT, US
    Thomas M. Stormann - Salt Lake City UT, US
    Scott T Moe - Marlborough UT, US
    Susan M Sheehan - Dexter MI, US
    Donald McLeod - Salt Lake City UT, US
    Daryl L Smith - Fishers IN, US
    Methvin Isaac - Toronto, CA
    Abdelmalik Slassi - Toronto, CA
    Ian Egle - Toronto, CA
    Louise Edwards - Toronto, CA
    Tomislav Stefanac - Toronto, CA
    Tao Xin - Toronto, CA
    Jalaj Arora - Toronto, CA
    William Michne - Wilmington DE, US
  • Assignee:
    NPS Pharmaceuticals, Inc. - Salt Lake City UT
    Astrazeneca AB - Sodertalje
  • International Classification:
    A61K 31/44
    C07D 401/02
  • US Classification:
    514340, 5462691
  • Abstract:
    The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

  • Human Metabotropic Glutamate Receptor

    view source
  • US Patent:
    7241863, Jul 10, 2007
  • Filed:
    Jan 17, 2003
  • Appl. No.:
    10/346241
  • Inventors:
    Karen J. Krapcho - Salt Lake City UT, US
    Thomas M. Stormann - Salt Lake City UT, US
    Cynthia Levinthal - Salt Lake City UT, US
    Lance G. Hammerland - Salt Lake City UT, US
    Laura Storjohann - Salt Lake City UT, US
  • Assignee:
    NPS Pharmaceuticals, Inc. - Salt Lake City UT
  • International Classification:
    C07K 14/00
  • US Classification:
    530350, 536 234, 435 691, 435 71
  • Abstract:
    A novel human metabotropic glutamate receptor (mGluR) protein is identified, sequenced, and cloned. The receptor may be used to screen for compounds that modulate the activity of the mGluR. The recombinant mGluR, as well as compounds that modulate mGluR activity, may be used in the diagnosis and treatment of neurological disorders and diseases.

  • Compounds

    view source
  • US Patent:
    7456200, Nov 25, 2008
  • Filed:
    Nov 14, 2005
  • Appl. No.:
    11/274611
  • Inventors:
    Jalaj Arora - Cambridge, CA
    Louise Edwards - Mississauga, CA
    Methvin Isaac - Etoicoke, CA
    Donald A. McLeod - Salt Lake City UT, US
    Abdelmalik Slassi - Mississauga, CA
    Tomislav Stefanac - Burlington, CA
    Thomas M. Stormann - Salt Lake City UT, US
    David Wensbo - Sodertalje, SE
    Tao Xin - Woodbridge, CA
    Helena Gyback - Sodertalje, SE
    Martin Johansson - Sodertalje, SE
    Annika Kers - Sodertalje, SE
    John Malmberg - Sodertalje, SE
    Alexander Minidis - Sodertalje, SE
    Karin Oscarsson - Sodertalje, SE
    Mangus Waldman - Sodertalje, SE
    Ulrika Yngve - Sodertalje, SE
    Christoffer Osterwall - Sodertalje, SE
  • Assignee:
    Astrazeneca AB - Sodertalje
  • International Classification:
    A61K 31/44
    C07D 413/14
  • US Classification:
    514340, 5462721
  • Abstract:
    The present invention relates to new compounds of formula I,.
Get Report for Thomas M Stormann from Salt Lake City, UT, age ~66
Control profile